{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T11:30:49Z","timestamp":1777116649713,"version":"3.51.4"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01-HL055502"],"award-info":[{"award-number":["R01-HL055502"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["U10 HL110262"],"award-info":[{"award-number":["U10 HL110262"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01-HL36634"],"award-info":[{"award-number":["R01-HL36634"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Institutes of Health Training","award":["T-91160"],"award-info":[{"award-number":["T-91160"]}]},{"DOI":"10.13039\/100006108","name":"National Centre for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR000135"],"award-info":[{"award-number":["UL1TR000135"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Heart Failure Network Clinical Research Skills Development","award":["HL084907"],"award-info":[{"award-number":["HL084907"]}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Guided by predictive characteristics of cardiovascular biomarkers, we explored the clinical implications of a simulated biomarker-guided heart failure (HF) and major adverse cardiovascular events (MACE) prevention strategy in the community.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>In a community cohort (n = 1824), the predictive characteristics for HF and MACE of galectin-3 (Gal-3), ST2, high-sensitivity cardiac troponin I (hscTnI), high-sensitivity C-reactive protein (hsCRP), N-terminal pro-brain natriuretic peptide (NT-proBNP) and B-type natriuretic peptide (BNP) were established. We performed number needed to screen (NNS) and treat (NNT) with the intervention analyses according to biomarker screening strategy and intervention efficacy in persons with at least one cardiovascular risk factor. In the entire cohort, for both HF and MACE, the predictive characteristics of NT-proBNP and hscTnI were superior to other biomarkers; alone, in a multimarker model, and adjusting for clinical risk factors. An NT-proBNP-guided preventative intervention with an intervention effect size (4-year hazard ratio for intervention in biomarker positive cohort) of \u22640.7 would reduce the global burden of HF by \u226520% and MACE by \u226515%. From this simulation, the NNS to prevent one HF event or MACE in 4 years would be \u2264100 with a NNT to prevent one HF event of \u226420 and one MACE of \u226410.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The predictive characteristics of NT-proBNP and hscTnI for HF or MACE in the community are superior to other biomarkers. Biomarker-guided preventative interventions with reasonable efficacy would compare favourably to established preventative interventions. This data provides a framework for biomarker selection which may inform design of biomarker-guided preventative intervention trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ejhf.663","type":"journal-article","created":{"date-parts":[[2016,11,4]],"date-time":"2016-11-04T01:48:20Z","timestamp":1478224100000},"page":"1342-1350","source":"Crossref","is-referenced-by-count":31,"title":["Biomarker-Based Risk Prediction in the Community"],"prefix":"10.1093","volume":"18","author":[{"given":"Omar F.","family":"AbouEzzeddine","sequence":"first","affiliation":[{"name":"Cardiorenal Research Laboratory"},{"name":"Department of Cardiovascular Diseases, Mayo Clinic and Foundation , Rochester, MN ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul M.","family":"McKie","sequence":"additional","affiliation":[{"name":"Cardiorenal Research Laboratory"},{"name":"Department of Cardiovascular Diseases, Mayo Clinic and Foundation , Rochester, MN ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher G.","family":"Scott","sequence":"additional","affiliation":[{"name":"Division of Biomedical Statistics and Informatics, Mayo Clinic and Foundation , Rochester, MN ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard J.","family":"Rodeheffer","sequence":"additional","affiliation":[{"name":"Cardiorenal Research Laboratory"},{"name":"Department of Cardiovascular Diseases, Mayo Clinic and Foundation , Rochester, MN ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Horng H.","family":"Chen","sequence":"additional","affiliation":[{"name":"Cardiorenal Research Laboratory"},{"name":"Department of Cardiovascular Diseases, Mayo Clinic and Foundation , Rochester, MN ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Michael Felker","sequence":"additional","affiliation":[{"name":"Department of Medicine, Duke University Medical Center , Durham, NC ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allan S.","family":"Jaffe","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Diseases, Mayo Clinic and Foundation , Rochester, MN ,","place":["USA"]},{"name":"Department of Laboratory Medicine and Pathology, Mayo Clinic and Foundation , Rochester, MN ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John C.","family":"Burnett","sequence":"additional","affiliation":[{"name":"Cardiorenal Research Laboratory"},{"name":"Department of Cardiovascular Diseases, Mayo Clinic and Foundation , Rochester, MN ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret M.","family":"Redfield","sequence":"additional","affiliation":[{"name":"Cardiorenal Research Laboratory"},{"name":"Department of Cardiovascular Diseases, Mayo Clinic and Foundation , Rochester, MN ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2016,11,4]]},"reference":[{"key":"2026011721163260300_ejhf663-bib-0001","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1373\/clinchem.2014.222778","article-title":"High-sensitivity troponin I and amino-terminal pro \u2013 B-type natriuretic peptide predict heart failure and mortality in the general population","volume":"60","author":"McKie","year":"2014","journal-title":"Clin Chem"},{"key":"2026011721163260300_ejhf663-bib-0002","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1161\/CIRCULATIONAHA.112.129437","article-title":"Prognostic utility of novel biomarkers of cardiovascular stress: the Framingham Heart Study","volume":"126","author":"Wang","year":"2012","journal-title":"Circulation"},{"key":"2026011721163260300_ejhf663-bib-0003","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1016\/j.jacc.2012.12.048","article-title":"Cardiac troponin I levels measured with a high-sensitive assay increase over time and are strong predictors of mortality in an elderly population","volume":"61","author":"Eggers","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026011721163260300_ejhf663-bib-0004","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/eurheartj\/eht406","article-title":"High population prevalence of cardiac troponin I measured by a high-sensitivity assay and cardiovascular risk estimation: the MORGAM Biomarker Project Scottish Cohort","volume":"35","author":"Zeller","year":"2014","journal-title":"Eur Heart J"},{"key":"2026011721163260300_ejhf663-bib-0005","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s10741-014-9446-7","article-title":"Prediction of clinical outcomes using B-type natriuretic peptides in the general population: a systematic review","volume":"19","author":"Don-Wauchope","year":"2014","journal-title":"Heart Fail Rev"},{"key":"2026011721163260300_ejhf663-bib-0006","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1161\/CIRCULATIONAHA.109.929661","article-title":"Multimarker approach for the prediction of heart failure incidence in the community","volume":"122","author":"Velagaleti","year":"2010","journal-title":"Circulation"},{"key":"2026011721163260300_ejhf663-bib-0007","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1161\/CIRCHEARTFAILURE.114.001185","article-title":"Clinical risk stratification optimizes value of biomarkers to predict new-onset heart failure in a community-based cohort","volume":"7","author":"Brouwers","year":"2014","journal-title":"Circ Heart Fail"},{"key":"2026011721163260300_ejhf663-bib-0008","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1016\/j.jacc.2010.05.049","article-title":"Assessment of conventional cardiovascular risk factors and multiple biomarkers for the prediction of incident heart failure and atrial fibrillation","volume":"56","author":"Smith","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2026011721163260300_ejhf663-bib-0009","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","article-title":"American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines. 2013 ACCF\/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"62","author":"Yancy","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026011721163260300_ejhf663-bib-0010","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1001\/jama.2013.7588","article-title":"Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial","volume":"310","author":"Ledwidge","year":"2013","journal-title":"JAMA"},{"key":"2026011721163260300_ejhf663-bib-0011","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.jacc.2013.05.069","article-title":"PONTIAC (NT-proBNP selected prevention of cardiac events in a population of diabetic patients without a history of cardiac disease): a prospective randomized controlled trial","volume":"62","author":"Huelsmann","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026011721163260300_ejhf663-bib-0012","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S0735-1097(02)02059-4","article-title":"Plasma brain natriuretic peptide concentration: impact of age and gender","volume":"40","author":"Redfield","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"2026011721163260300_ejhf663-bib-0013","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.annepidem.2003.11.001","article-title":"Participation bias in a population-based echocardiography study","volume":"14","author":"Jacobsen","year":"2004","journal-title":"Ann Epidemiol"},{"key":"2026011721163260300_ejhf663-bib-0014","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1016\/j.jacc.2010.01.031","article-title":"The prognostic value of N-terminal pro-B-type natriuretic peptide for death and cardiovascular events in healthy normal and stage A\/B heart failure subjects","volume":"55","author":"McKie","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2026011721163260300_ejhf663-bib-0015","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1001\/jama.289.2.194","article-title":"Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic","volume":"289","author":"Redfield","year":"2003","journal-title":"JAMA"},{"key":"2026011721163260300_ejhf663-bib-0016","doi-asserted-by":"crossref","first-page":"266","DOI":"10.4065\/71.3.266","article-title":"History of the Rochester Epidemiology Project","volume":"71","author":"Melton","year":"1996","journal-title":"Mayo Clin Proc"},{"key":"2026011721163260300_ejhf663-bib-0017","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4","article-title":"Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors","volume":"15","author":"Harrell","year":"1996","journal-title":"Stat Med"},{"key":"2026011721163260300_ejhf663-bib-0018","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0167-9473(98)00096-6","article-title":"An application of changepoint methods in studying the effect of age on survival in breast cancer","volume":"30","author":"Contal","year":"1999","journal-title":"Comput Statist Data Anal"},{"key":"2026011721163260300_ejhf663-bib-0019","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1161\/CIRCHEARTFAILURE.111.964841","article-title":"Prediction of incident heart failure in general practice: the Atherosclerosis Risk in Communities (ARIC) Study","volume":"5","author":"Agarwal","year":"2012","journal-title":"Circ Heart Fail"},{"key":"2026011721163260300_ejhf663-bib-0020","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1016\/j.jacc.2013.11.005","article-title":"American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. 2013 ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"Goff","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2026011721163260300_ejhf663-bib-0021","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jacc.2012.04.053","article-title":"Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community","volume":"60","author":"Ho","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2026011721163260300_ejhf663-bib-0022","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.ahj.2013.12.031","article-title":"Galectin-3 is independently associated with cardiovascular mortality in community-dwelling older adults without known cardiovascular disease: the Rancho Bernardo Study","volume":"167","author":"Daniels","year":"2014","journal-title":"Am Heart J"},{"key":"2026011721163260300_ejhf663-bib-0023","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1365-2796.2011.02476.x","article-title":"The fibrosis marker galectin-3 and outcome in the general population","volume":"272","author":"de Boer","year":"2012","journal-title":"J Intern Med"},{"key":"2026011721163260300_ejhf663-bib-0024","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/ejhf.21","article-title":"Plasma galectin 3 and heart failure risk in the Physicians\u2019 Health Study","volume":"16","author":"Djousse","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"2026011721163260300_ejhf663-bib-0025","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1136\/heartjnl-2014-305968","article-title":"FINRISK and BiomarCaRE Investigators. ST2 may not be a useful predictor for incident cardiovascular events, heart failure and mortality","volume":"100","author":"Hughes","year":"2014","journal-title":"Heart"},{"key":"2026011721163260300_ejhf663-bib-0026","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.jchf.2014.02.005","article-title":"Charting a roadmap for heart failure biomarker studies","volume":"2","author":"Ahmad","year":"2014","journal-title":"JACC Heart Fail"},{"key":"2026011721163260300_ejhf663-bib-0027","first-page":"2975","article-title":"Cholesterol, not just cardiovascular risk, is important in deciding who should receive statin treatment","volume":"36","author":"Soran","year":"2015","journal-title":"Eur Heart J"},{"key":"2026011721163260300_ejhf663-bib-0028","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s11886-015-0666-9","article-title":"Risk stratification for primary prevention of coronary artery disease: roles of c-reactive protein and coronary artery calcium","volume":"17","author":"Qureshi","year":"2015","journal-title":"Curr Cardiol Rep"},{"key":"2026011721163260300_ejhf663-bib-0029","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1161\/CIRCOUTCOMES.109.848473","article-title":"JUPITER Study Group. Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER)","volume":"2","author":"Ridker","year":"2009","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2026011721163260300_ejhf663-bib-0030","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1002\/ejhf.286","article-title":"Cost-effectiveness of natriuretic peptide-based screening and collaborative care: a report from the STOP-HF (St Vincent\u2019s Screening TO Prevent Heart Failure) study","volume":"17","author":"Ledwidge","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"2026011721163260300_ejhf663-bib-0031","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A randomized trial of intensive versus standard blood-pressure control","volume":"373","author":"SPRINT Research Group","year":"2015","journal-title":"N Engl J Med"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fejhf.663","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/18\/11\/1342\/66379607\/eurjhf_18_11_1342.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/18\/11\/1342\/66379607\/eurjhf_18_11_1342.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T02:17:21Z","timestamp":1768702641000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/18\/11\/1342\/8423103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,1]]},"references-count":31,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2016,11,4]]},"published-print":{"date-parts":[[2016,11,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.663","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2016,11]]},"published":{"date-parts":[[2016,11,1]]}}}